The Drug Price Transparency in Medicaid Act will protect patients, pharmacies, and others from middlemen tactics that drive up prescription drug prices.
Pharmacy benefit manager (PBM) reform; comprehensive direct and indirect remuneration (DIR) fee reform; and sustaining patient access to vaccinations, testing, and treatment among key topics at the February 28-March 1 program.
U.S. House Oversight and Accountability Committee expands bipartisan Congressional push to stop pharmaceutical benefit manipulation by middlemen.
Statement outlines specific solutions to patient-manipulation by “PBMs”.
NACDS President and CEO Steven C. Anderson issued the following statement, upon the release of a U.S. Department of Health and Human Services (HHS) Fact Sheet describing decision-making underway about implications of the May 11, 2023, expiration of the current Public Health Emergency (PHE).
With the U.S. House of Representatives slated to consider legislation related to the pandemic this week, NACDS has an important message: constituents view the importance of pharmacy access as a lesson that must be learned from the past three years.
The NACDS-authored column previews the policy outlook for the coming year — and what lies ahead for the future of the industry.
Inclusion of the INFORM Consumers Act marks a major bipartisan step toward curbing the organized retail crime networks jeopardizing Americans’ safety.
NACDS details actions needed by Biden Administration and Congress to prevent forced rollback
Through NACDS 2023, the Association continues to advance consumer-empowered, community-focused health and wellness.
